Abstract
High pressure liquid chromatography (HPLC) fractionation of the cerebrospinal fluid (CSF) from sleep-deprived cats led to the detection of a substance that accumulated under conditions of sleep deprivation [1]. FABHRMS provided a best-fit molecular formula of C18H35NO and MS2/MS3revealed a lipid fragmentation pattern. Given the simplicity of the molecule, candidate lipid structures incorporating the molecular formula and correct degree of unsaturation were prepared and correlated with the endogenous substance (Fig. 1) [2]. Oleamide (1) proved identical with the authentic material and, with a recognition of its characteristics and solubility properties, sufficient amounts (300–400 μg) of the endogenous lipid were isolated from the CSF to permit an unambiguous correlation [2, 3]. Oleamide was shown to induce physiological sleep in rats, mice, and cats in a dose-dependent manner [3]. As in physiological sleep, the sleeping animals maintained the ability to respond to sound with an orienting reflex and attention directed toward the source. The examination of a number of close structural analogues revealed that this effect is specific for oleamide. These studies identified oleamide as an endogenous signaling fatty acid amide and provided the second prototypical member of a new and growing class of signaling molecules: fatty acid amides [4, 5].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lerner RA, Siuzdak G, Prospero-Garcia O, Henriksen SJ, Boger DL, Cravatt BF (1994) Cerebrodiene: a brain lipid isolated from sleep-deprived cats. Proc Natl Acad Sci USA 91:9505–9508
Cravatt BF, Lerner RA, Boger DL (1996) Structure determination of an endogenous sleep-inducing lipid, cis-9-octadecenoamide (oleamide): a synthetic approach to the chemical analysis of trace quantities of a natural product. J Am Chem Soc 118:580–590
Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA (1995) Chemical characterization of a family of brain lipids that induce sleep. Science 268:1506–1509
Boger DL, Henriksen SJ, Cravatt BF (1998) Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des 4:303–314
Ezzili C, Otrubova K, Boger DL (2010) Fatty acid amide signaling molecules. Bioorg Med Chem Lett 20:5959–5968
Wilcox BJ, Ritenour-Rodgers KJ, Asser AS, Baumgart LE, Baumgart MA, Boger DL, Patterson JE, DeBlassio JL, deLong MA, Glufke U, Henz ME, King L III, Merkler KA, Robleski JJ, Vederas JC, Merkler DJ (1999) N-acylglycine amidation: implications for the biosynthesis of fatty acid primary amides. Biochemistry 38:3235–3245
Boger DL, Patterson JE, Jin Q (1998) Structural requirements for 5-HT2Aand 5-HT1Areceptor potentiation by the biologically active lipid oleamide. Proc Natl Acad Sci USA 95:4102–4107
Yost CS, Hampson AJ, Leonoudakis D, Koblin DD, Bornheim LM, Gray AT (1998) Oleamide potentiates benzodiazepine-sensitive gamma-aminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration. Anesth Analg 86:1294–1300
Verdon B, Zheng J, Nicholson RA, Ganellin CR, Lees G (2000) Stereoselective modulatory actions of oleamide on GABAAreceptors and voltage-gated Na+channels in vitro: a putative endogenous ligand for depressant drug sites in the CNS. Br J Pharmacol 129:283–290
Nicholson RA, Zheng J, Ganellin CR, Verdon B, Less G (2001) Anesthetic-like interaction of the sleep-inducing lipid oleamide with voltage-gated sodium channels in mammalian brain. Anesthesia 94:120–128
Guan X, Cravatt BF, Ehring GR, Hall JE, Boger DL, Lerner RA, Gilula NB (1997) The sleep-inducing lipid oleamide deconvolutes gap junction communication and calcium wave transmission in glial cells. J Cell Biol 139:1785–1792
Boger DL, Patterson JE, Guan X, Cravatt BF, Lerner RA, Gilula NB (1998) Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc Natl Acad Sci USA 95:4810–4815
Boger DL, Sato H, Lerner AE, Guan X, Gilula NB (1999) Arachidonic acid amide inhibitors of gap junction cell–cell communication. Bioorg Med Chem Lett 9:1151–1154
Fedorova I, Hashimoto A, Fecik RA, Hedrick MP, Hanus LO, Boger DL, Rice KC, Basile AS (2001) Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J Pharmacol Exp Ther 299:332–342
Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature (Lond) 384:83–87
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949
Giang DK, Cravatt BF (1997) Molecular characterization of human and mouse fatty acid amide hydrolase. Proc Natl Acad Sci USA 94:2238–2242
Cravatt BF, Lichtman AH (2003) Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469–775
Thomas EA, Cravatt BF, Danielson PE, Gilula NB, Sutcliffe JG (1997) Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J Neurosci Res 50:1047–1052
Egertova M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119:481–496
McKinney MK, Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411–432
Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98:9371–9376
Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S, Starowicz K, Steuder R, Schlicker E, Cravatt BF, Mechoulam R, Buettner R, Werner S, Di Marzo V, Tueting T, Zimmer A (2007) Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316:1494–1497
Huitrón-Reséndiz S, Sanchez-Alavez M, Wills DN, Cravatt BF, Henriksen SJ (2004) Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase. Sleep 27:857–865
Boger DL, Fecik RA, Patterson JE, Miyauchi H, Patricelli MP, Cravatt BF (2000) Fatty acid amide hydrolase substrate specificity. Bioorg Med Chem Lett 10:2613–2616
Patterson JE, Ollmann IR, Cravatt BF, Boger DL, Wong C-H, Lerner RA (1996) Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid: cis-9-octadecenamide. J Am Chem Soc 118:5938–5945
Boger DL, Sato H, Lerner AE, Austin BJ, Patterson JE, Patricelli MP, Cravatt BF (1999) Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg Med Chem Lett 9:265–270
Patricelli MP, Patterson JE, Boger DL, Cravatt BF (1998) An endogenous REM sleep inducing compound is a potent competitive inhibitor of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 8:613–618
Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyauchi H, Wilkie GD, Austin BJ, Patricelli MP, Cravatt B (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 97:5044–5049
Boger DL, Miyauchi H, Hedrick MP (2001) α-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and α-substitution. Bioorg Med Chem Lett 11:1517–1520
Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimaráes CRW, Jorgensen WL, Cravatt BF (2005) Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase as analgesics. J Med Chem 48:1849–1856
Leung D, Du W, Hardouin C, Cheng H, Hwang I, Cravatt BF, Boger DL (2005) Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. Bioorg Med Chem Lett 15:1423–1428
Romero FA, Du W, Hwang I, Rayl TJ, Kimball FS, Leung D, Hoover HS, Apodaca RL, Breitenbucher JG, Cravatt BF, Boger DL (2007) Potent and selective α-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. J Med Chem 50:1058–1068
Hardouin C, Kelso MJ, Romero FA, Rayl TJ, Leung D, Hwang I, Cravatt BF, Boger DL (2007) Structure–activity relationships of α-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem 50:3359–3368
Kimball FS, Romero FA, Ezzili C, Garfunkle J, Rayl TJ, Hochstatter DG, Hwang I, Boger DL (2008) Optimization of α-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem 51:937–947
Garfunkle J, Ezzili C, Rayl TJ, Hochstatter DG, Hwang I, Boger DL (2008) Optimization of the central heterocycle of α-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 51:4393–4403
Ezzili C, Mileni M, McGlinchey N, Long JZ, Kinsey SG, Hochstatter DG, Stevens RC, Lichtman AH, Cravatt BF, Bilsky EJ, Boger DL (2011) Reversible competitive α-ketoheterocycle inhibitors of fatty acid amide hydrolase containing additional conformational constraints in the acyl side chain: orally active, long acting analgesics. J Med Chem 54:2805–2822
Guimaráes CRW, Boger DL, Jorgensen WL (2005) Elucidation of fatty acid amide hydrolase inhibition by potent α-ketoheterocycle derivatives from Monte Carlo simulations. J Am Chem Soc 127:17377–17384
Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441–448
Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH (2009) Endocannabinoid modulation of scratching response in an acute allergenic model: new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther 329:314–323
Kinsey SG, Long JZ, O’Neal ST, Abdulla RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902–910
Romero FA, Hwang I, Boger DL (2006) Delineation of a fundamental α-ketoheterocycle substituent effect for use in the design of enzyme inhibitors. J Am Chem Soc 128:14004–14005
DeMartino JK, Garfunkle J, Hochstatter DG, Cravatt BF, Boger DL (2008) Exploration of a fundamental substituent effect of α-ketoheterocycle enzyme inhibitors: potent and selective inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 18:5842–5846
Liu Y, Patricelli MP, Cravatt BF (1999) Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci USA 96:14694–14699
Leung D, Hardouin C, Boger DL, Cravatt BF (2003) Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol 21:687–691
Mileni M, Garfunkle J, DeMartino JK, Cravatt BF, Boger DL, Stevens RC (2009) Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by α-ketoheterocycle inhibitors revealed from cocrystal structures. J Am Chem Soc 131:10497–10506
Mileni M, Garfunkle J, Kimball FS, Cravatt BF, Stevens RC, Boger DL (2010) X-ray crystallographic analysis of α-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem 53:230–240
Mileni M, Garfunkle J, Ezzili C, Cravatt BF, Stevens RC, Boger DL (2011) Fluoride-mediated capture of a noncovalent bound state of a reversible covalent enzyme inhibitor: X-ray crystallographic analysis of an exceptionally potent α-ketoheterocycle inhibitor of fatty acid amide hydrolase. J Am Chem Soc 133:4092–4100
Acknowledgments
We gratefully acknowledge the financial support of the National Institutes of Health (DA015648), and the efforts of our long-time collaborators (R.A. Lerner, B.F. Cravatt, S.J. Henriksen, N.B. Gilula, G. Siuzdak, A.H. Lichtman, E.J. Bilsky, and R.C. Stevens).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer
About this paper
Cite this paper
Boger, D.L. (2012). Inhibitors of Fatty Acid Amide Hydrolase. In: Shibasaki, M., Iino, M., Osada, H. (eds) Chembiomolecular Science. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54038-0_4
Download citation
DOI: https://doi.org/10.1007/978-4-431-54038-0_4
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54037-3
Online ISBN: 978-4-431-54038-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)